ALK1 as an emerging target for antiangiogenic therapy of cancer - Test2 - elhamkhani - TriplyDB

ALK1 as an emerging target for antiangiogenic therapy of cancer

ALK1 as an emerging target for antiangiogenic therapy of cancer

http://www.wikidata.org/entity/Q35127963

about

Signal transduction inhibitors in treatment of myelodysplastic syndromes Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling.Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway.Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides.Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14 Biomarkers in tumor angiogenesis and anti-angiogenic therapy.A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.Decreasing matrix modulus of PEG hydrogels induces a vascular phenotype in human cord blood stem cells BMP9 and BMP10 are critical for postnatal retinal vascular remodeling.Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N Increased caveolin-1 in intervertebral disc degeneration facilitates repair Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination BMP9 signaling in stem cell differentiation and osteogenesis.Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis.Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development.Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation Systemic neutralization of TGF-β attenuates osteoarthritis Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone.Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6.Novel targets for VEGF-independent anti-angiogenic drugs.The expression of activin receptor-like kinase 1 among patients with head and neck cancer.Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?Therapies currently in Phase II trials for malignant pleural mesothelioma.Understanding and targeting resistance to anti-angiogenic therapies.Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Therapy of advanced squamous cell carcinoma of the skin.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cells TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.Detecting and targetting oncogenic fusion proteins in the genomic era.

P2860

Q26829903-E3C107DD-7C1D-44BA-8752-664D9664B922 Q27681271-94021EA0-88B1-4ECF-AE3F-442C67DCDC85 Q28296361-D4896DC6-F0A8-4645-89B1-EB359D207257 Q28508560-808E9DCC-9B79-46FF-A984-BE9299354850 Q30540454-B22C1D6B-E845-4FA7-8ADE-0AB4B48E0EE3 Q33431483-2FC497C0-7B5F-4E3F-884A-232F262076A7 Q33433311-B5B06725-7C5A-4D11-8925-08154A2F753A Q33719706-D264E60D-3049-4CCE-A327-BB9575660431 Q33779258-C778B337-05D6-45DC-920E-D254447D626E Q34505275-E7D4B3D3-537A-4C42-8BB8-D949A44019A6 Q34540047-2E004ED4-5D3F-4ECA-B481-BF2E526BA0EF Q35170438-967DD21F-E141-4BB3-BD14-C154D6FA93AB Q35536088-33B22889-9286-42ED-90A7-82D10532FBAF Q35547649-AB413AF2-A037-4860-9DB2-5B466DD3F869 Q35752197-1ED79099-631C-4E6F-9576-CACE410B9244 Q36057921-34019399-5B99-41A7-8961-7EB6D6881B70 Q36191443-DC3E5FF1-253C-4C24-A9DA-7C055EFFDE2A Q36651774-C536E13D-10FF-4E4C-8CBE-1F8D7F49ADDD Q36694132-1E3F07A5-48BE-4A61-9C95-9A6EC27E70AC Q36796379-663101FF-A537-4225-90DB-8785B8E2F0C1 Q36927604-CA75F830-BD57-4B1A-A9ED-0D36F9509F3D Q37031726-4AE356D8-4D65-4140-AC89-1B1DE7BAF852 Q37047011-A617F76F-E883-40B0-B484-6E2107EEB00A Q37146817-440C8137-2FE1-493D-BAB2-77E86FBBDBBD Q37235742-1C705E25-1B72-4834-9934-76A5E9D8B816 Q37340780-23439839-6DB9-43B4-972C-0A8BA3849F9D Q37611674-3F9503A4-EC7E-4EE0-9CC0-E282FF7CF773 Q37683823-97051A97-7C55-411E-8D0A-500F060330FC Q37984612-ECD8DCCE-FA6A-45CC-853B-7BAEF05C972C Q38085283-846C9E62-BDE0-43BB-B44F-2BFAF51F9215 Q38115632-333A7A0C-1E81-40EF-A61C-1D604BA59A01 Q38118385-7F76E52A-166F-474F-95D8-94C1C556292E Q38133568-57F0A4C9-37FD-48EE-9F63-F36B2ECAA3FA Q38140116-BA59FE6B-6B27-4821-AA59-1E80FF627FCE Q38174516-ACC79747-BF90-47ED-9192-8DAD77A1732B Q38197119-9CEFDB01-8413-4FF4-8620-A7C94265930F Q38221292-3F303AB4-985D-4492-AFAA-496A19E9C36B Q38233800-7CBC287B-839E-4582-AE8D-DF5971913C29 Q38256407-F5C57119-A362-448B-BE2A-D81D39531F4E Q38336067-36A4EBEA-639F-4BF0-A99E-5138A96D02D8

P2860

ALK1 as an emerging target for antiangiogenic therapy of cancer

http://www.wikidata.org/entity/Q35127963

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

ALK1 as an emerging target for antiangiogenic therapy of cancer

@ast

ALK1 as an emerging target for antiangiogenic therapy of cancer

@en

type

label

ALK1 as an emerging target for antiangiogenic therapy of cancer

@ast

ALK1 as an emerging target for antiangiogenic therapy of cancer

@en

prefLabel

ALK1 as an emerging target for antiangiogenic therapy of cancer

@ast

ALK1 as an emerging target for antiangiogenic therapy of cancer

@en

P1433

Q35127963-2862199B-7625-4B10-829F-295DE87DD4C2

P1476

Q35127963-C32C0508-3941-4503-AB62-66AE6E27F4E5

P2093

Q35127963-8887C087-64EB-4CE7-9002-021492F99AE7

Q35127963-CE50021B-0197-4B09-A587-CA815E725854

P2860

Q35127963-005D838F-0B24-442B-92AC-B37481DE7479

Q35127963-0658A46E-62AD-4A06-906B-E1BE42144897

Q35127963-083B2B78-ED46-4286-B475-D9F33757FDDD

Q35127963-0851467A-9436-477F-9CBF-3720E53C691F

Q35127963-09216C08-B673-45E4-B7BC-6C6D03CADC4C

Q35127963-09A4F1A8-AB27-4D0E-A04B-07241C177E10

Q35127963-0A0B0672-F941-4E3C-91C1-7303E4AB2EA7

Q35127963-0B1644C2-CC7D-4EE5-A589-B4DA31E7580A

Q35127963-0DEBA1B8-6795-4CA6-B194-88F9569A3006

Q35127963-0E17AF6B-2551-47EB-BB71-39BDBA274BF7

P304

Q35127963-2226BD60-DACC-4602-BBF7-40D72C2B3FC7

P31

Q35127963-94A14091-60C1-43BB-BC90-77A0476C55D2

P356

Q35127963-0C9A195C-750C-479B-B82F-01B2EF3AC7DE

P407

Q35127963-D6A2A4F0-CCA0-4427-ABC6-98AE01F701AE

P433

Q35127963-9088B95B-D65C-4313-89E4-785FB992C583

P478

Q35127963-7B9967EB-DACC-4520-9638-635C3381A3C2

P577

Q35127963-44CACB99-7A81-45EB-9B95-38EE547BB69D

P5875

Q35127963-FBB6A56B-03BA-43AF-9DC7-7E0334042ADE

P698

Q35127963-86D67986-046B-4F6A-A52F-B57952FD3780

P932

Q35127963-473C655B-108B-4245-AEC7-6EF054D7D5D8

P356

BLOOD-2011-01-330142

P1433

P1476

ALK1 as an emerging target for antiangiogenic therapy of cancer

@en

P2093

Kristian Pietras

http://www.w3.org/2001/XMLSchema#string

Sara I Cunha

http://www.w3.org/2001/XMLSchema#string

P2860

Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily

Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling

Signal transduction of bone morphogenetic protein receptors

BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo

Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells

MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling

BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4

Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells

ALK1 signaling regulates early postnatal lymphatic vessel development

P304

6999-7006

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-01-330142

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51020125

http://www.w3.org/2001/XMLSchema#string

P698

21467543

http://www.w3.org/2001/XMLSchema#string

P932

3143549

http://www.w3.org/2001/XMLSchema#string